Kyntra Bio Scores First Analyst Coverage: Oppenheimer Initiates Outperform with $35 Target
Kyntra Bio gains analyst support as its cancer drugs advance, with key Phase 2 data expected to drive future growth.
NOTRELOAD AI
Aligos Therapeutics Shares Soar on Major China Licensing Agreement and Regulatory Milestone for Chronic Hepatitis B Treatment
Aligos Therapeutics announces $25 million upfront payment and Breakthrough Therapy Designation in China for pevifoscorvir sodium.
Vertex to Acquire Crinetics for $10 Billion in Major Rare Disease Expansion
The deal adds PALSONIFY (paltusotine) and late-stage CAH therapy to Vertex’s portfolio.
Ondas Acquires DZYNE Technologies for $876 Million, Launches Ondas Sentinel Defense Division
The move strengthens its U.S. defense portfolio and raises 2026 revenue guidance to $525M.
Vista Equity and Quinti Capital Bid for Criteo in Deal Valued at 50% Premium
French commerce media company Criteo gets takeover proposal from Vista Equity and Quinti Capital at over 50% premium to current share price.
Apollo Eyes Full Acquisition of GFL as CEO Patrick Dovigi Prepares to Take Company Private
Special committee evaluating options.